AUD 0.03
(13.64%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 | -5.43 Million USD | -10.29% |
2023 | -4.92 Million USD | 77.07% |
2022 | -18.67 Million USD | -74.64% |
2021 | -10.69 Million USD | -2.66% |
2020 | -10.41 Million USD | -277.48% |
2019 | -2.75 Million USD | -124.52% |
2018 | -1.22 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q4 | -842.25 Thousand USD | -21.83% |
2024 Q1 | -2.19 Million USD | -33.92% |
2024 Q2 | -2.19 Million USD | 0.0% |
2024 Q3 | -691.33 Thousand USD | 68.45% |
2023 Q2 | -1.93 Million USD | 0.0% |
2023 FY | - USD | 77.07% |
2023 Q4 | -1.63 Million USD | -17.32% |
2023 Q3 | -1.39 Million USD | 27.9% |
2023 Q1 | -1.93 Million USD | 75.66% |
2022 Q2 | -4.88 Million USD | 0.0% |
2022 Q1 | -4.88 Million USD | -16.36% |
2022 FY | - USD | -74.64% |
2022 Q4 | -7.94 Million USD | 0.0% |
2022 Q3 | -7.94 Million USD | -62.63% |
2021 FY | - USD | -2.66% |
2021 Q4 | -4.19 Million USD | 0.0% |
2021 Q3 | -4.19 Million USD | -266.45% |
2021 Q2 | -1.14 Million USD | 0.0% |
2021 Q1 | -1.14 Million USD | 66.0% |
2020 Q4 | -3.37 Million USD | -10.75% |
2020 Q2 | -1.91 Million USD | -3.96% |
2020 Q1 | -1.84 Million USD | 0.0% |
2020 FY | - USD | -277.48% |
2020 Q3 | -3.04 Million USD | -59.08% |
2019 FY | - USD | -124.52% |
2018 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Australian Clinical Labs Limited | 181.83 Million AUD | 102.99% |
BCAL Diagnostics Limited | -5.66 Million AUD | 4.073% |
Genetic Signatures Limited | -20.33 Million AUD | 73.272% |
Genetic Technologies Limited | -11.43 Million AUD | 52.444% |
Healius Limited | -298.09 Million AUD | 98.176% |
Imagion Biosystems Limited | -13.69 Million AUD | 60.312% |
Integral Diagnostics Limited | 12.33 Million AUD | 144.073% |
INOVIQ Ltd | -6.63 Million AUD | 18.051% |
Microba Life Sciences Limited | -22.8 Million AUD | 76.167% |
Monash IVF Group Limited | 13.02 Million AUD | 141.735% |
Rhythm Biosciences Limited | -6.79 Million AUD | 20.011% |
Sonic Healthcare Limited | 1.65 Billion AUD | 100.328% |